Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectis S.A. ADR (NQ: CLLS )

1.760 -0.040 (-2.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. ADR

< Previous 1 2 3 4 5 6 7 Next >
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
From Cellectis Inc.
Via GlobeNewswire
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Earnings Preview: Cellectis
Via Benzinga
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders. 
Via Benzinga
Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning! 
Via InvestorPlace
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
From Cellectis Inc.
Via GlobeNewswire
Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged
U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision. The Dow traded up 0.40% to 33,185.41 while the NASDAQ rose 0.92% to 12,969.54. The S&P 500... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?
Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company  
Via Benzinga
Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.55% to 33,233.33 while the NASDAQ rose 0.87% to 12,962.92. The... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected
U.S. stocks traded mixed this morning, ahead of interest rate decision from the Federal Reserve. Following the market opening Wednesday, the Dow traded down 0.05% to 33,036.63 while the NASDAQ rose... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Is WeWork (WE) Stock Down 38% Today?
WeWork stock is falling on Wednesday as investors in WE shares react to reports that the company is considering a bankruptcy filing. 
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Is Paycom Software (PAYC) Stock Down 39% Today?
Paycom Software stock is falling hard on Wednesday as investors in PAYC go over the company's mixed earnings report for Q3 2023! 
Via InvestorPlace
Why Is Mainz Biomed (MYNZ) Stock Moving Today?
Mainz Biomed stock is on the move Wednesday as investors in MYNZ react to results from a colorectal cancer screening test campaign. 
Via InvestorPlace
Why Is Cellectis (CLLS) Stock Up 175% Today?
Cellectis stock is taking off on Wednesday as investors in CLLS react to a massive $245 million investment from AstraZeneca. 
Via InvestorPlace
Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today! 
Via InvestorPlace
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
From Cellectis Inc.
Via GlobeNewswire
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
From Cellectis Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.